Opus Genetics Inc (IRD)

$1.07 -0.04 (-3.60%)
Market Cap 63.84M
Revenue (ttm) 10.99M
Net Income (ttm) -57.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -523.48%
Debt to Equity Ratio 0.00
Volume 139,900
Avg Vol 1,285,250
Day's Range N/A - N/A
Shares Out 59.66M
Stochastic %K 6%
Beta 0.01
Analysts Strong Sell
Price Target $9.25

Company Profile

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal do...

Industry: Biotechnology
Sector: Healthcare
Phone: 984 884 6030
Website: opusgtx.com
Address:
8 Davis Drive, Suite 220, Durham, United States
Pharma_Stock_Calls
Pharma_Stock_Calls Jul. 31 at 2:41 PM
✅ 💊 $IRD Entry: $1.08 → Target: $1.18
0 · Reply
JoeD32
JoeD32 Jul. 31 at 12:39 PM
$IRD Back in its hole until the next 50 cent pump and dump
0 · Reply
JoeD32
JoeD32 Jul. 23 at 3:11 PM
$IRD these guys need to stop dropping news articles…everytime sends it back in the hole 🤣
2 · Reply
prismmarketview
prismmarketview Jul. 23 at 1:20 PM
Nasdaq: $IRD Opus Genetics and the Global RDH12 Alliance are teaming up to accelerate development of a gene therapy for RDH12-associated Leber congenital amaurosis (RDH12-LCA), a rare and severe form of childhood blindness. #OpusGenetics https://prismmarketview.com/opus-genetics-and-global-rdh12-alliance-join-forces-to-accelerate-gene-therapy-for-childhood-blindness/
0 · Reply
Novice1a
Novice1a Jul. 23 at 1:15 PM
$IRD https://ir.opusgtx.com/press-releases/detail/492/opus-genetics-and-the-global-rdh12-alliance-partner-to-advance-rdh12-gene-therapyfor-inherited-childhood-blindness
0 · Reply
JussieLivermore
JussieLivermore Jul. 23 at 1:08 PM
$IRD Notice APX3330 is referenced in latest PR? Wonder why it was left out in last Corporate Presentation? Sloppy
0 · Reply
t_baggin_u
t_baggin_u Jul. 23 at 10:11 AM
$IRD It's working its way up day by day, bit by bit for one month now. I wouldn't be surprised if a catalyst comes soon. 🍀
0 · Reply
signaljumper
signaljumper Jul. 22 at 9:11 PM
$IRD this Stock ist still cheap. Sooner or later this Stock will trade much Higher
0 · Reply
Um8a123
Um8a123 Jul. 22 at 7:52 PM
$IRD One of these days we’re gonna wake up to 7
1 · Reply
signaljumper
signaljumper Jul. 16 at 7:32 PM
$IRD this biotech lowfloatvsrock will run very soon. Accunulation mode before the run
0 · Reply
Latest News on IRD
Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Jul 23, 2025, 8:00 AM EDT - 10 days ago

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 3, 2025, 4:30 PM EDT - 4 weeks ago

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Jun 26, 2025, 6:55 AM EDT - 5 weeks ago

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

Jun 23, 2025, 8:00 AM EDT - 5 weeks ago

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Jun 2, 2025, 8:00 AM EDT - 2 months ago

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

May 15, 2025, 8:00 AM EDT - 2 months ago

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

May 12, 2025, 8:00 AM EDT - 2 months ago

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

May 6, 2025, 8:00 AM EDT - 3 months ago

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

May 5, 2025, 8:00 AM EDT - 3 months ago

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Apr 11, 2025, 3:47 PM EDT - 4 months ago

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Apr 8, 2025, 8:00 AM EDT - 4 months ago

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Opus Genetics to Participate in Upcoming Investor Conference in April

Apr 2, 2025, 8:00 AM EDT - 4 months ago

Opus Genetics to Participate in Upcoming Investor Conference in April

Opus Genetics Announces Financial Results for Full Year 2024

Mar 31, 2025, 8:20 AM EDT - 4 months ago

Opus Genetics Announces Financial Results for Full Year 2024

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Mar 21, 2025, 5:03 PM EDT - 4 months ago

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Mar 21, 2025, 9:30 AM EDT - 4 months ago

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Mar 21, 2025, 9:11 AM EDT - 4 months ago

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 19, 2025, 3:56 PM EDT - 4 months ago

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Mar 5, 2025, 8:00 AM EST - 5 months ago

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Feb 26, 2025, 8:00 AM EST - 5 months ago

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Feb 18, 2025, 7:30 AM EST - 5 months ago

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

Feb 7, 2025, 9:15 AM EST - 6 months ago

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

XBI

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Dec 19, 2024, 8:00 AM EST - 8 months ago

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Pharma_Stock_Calls
Pharma_Stock_Calls Jul. 31 at 2:41 PM
✅ 💊 $IRD Entry: $1.08 → Target: $1.18
0 · Reply
JoeD32
JoeD32 Jul. 31 at 12:39 PM
$IRD Back in its hole until the next 50 cent pump and dump
0 · Reply
JoeD32
JoeD32 Jul. 23 at 3:11 PM
$IRD these guys need to stop dropping news articles…everytime sends it back in the hole 🤣
2 · Reply
prismmarketview
prismmarketview Jul. 23 at 1:20 PM
Nasdaq: $IRD Opus Genetics and the Global RDH12 Alliance are teaming up to accelerate development of a gene therapy for RDH12-associated Leber congenital amaurosis (RDH12-LCA), a rare and severe form of childhood blindness. #OpusGenetics https://prismmarketview.com/opus-genetics-and-global-rdh12-alliance-join-forces-to-accelerate-gene-therapy-for-childhood-blindness/
0 · Reply
Novice1a
Novice1a Jul. 23 at 1:15 PM
$IRD https://ir.opusgtx.com/press-releases/detail/492/opus-genetics-and-the-global-rdh12-alliance-partner-to-advance-rdh12-gene-therapyfor-inherited-childhood-blindness
0 · Reply
JussieLivermore
JussieLivermore Jul. 23 at 1:08 PM
$IRD Notice APX3330 is referenced in latest PR? Wonder why it was left out in last Corporate Presentation? Sloppy
0 · Reply
t_baggin_u
t_baggin_u Jul. 23 at 10:11 AM
$IRD It's working its way up day by day, bit by bit for one month now. I wouldn't be surprised if a catalyst comes soon. 🍀
0 · Reply
signaljumper
signaljumper Jul. 22 at 9:11 PM
$IRD this Stock ist still cheap. Sooner or later this Stock will trade much Higher
0 · Reply
Um8a123
Um8a123 Jul. 22 at 7:52 PM
$IRD One of these days we’re gonna wake up to 7
1 · Reply
signaljumper
signaljumper Jul. 16 at 7:32 PM
$IRD this biotech lowfloatvsrock will run very soon. Accunulation mode before the run
0 · Reply
ztocklydotcom
ztocklydotcom Jul. 13 at 3:41 PM
$IRD A golden barcode detected with our patent-pending system. Still early in the backtesting stages, should have all the data needed by September to file for the patent. A golden barcode doesn’t mean something explosive is on the horizon, but potential energy releasing soon.
0 · Reply
LookinForGains
LookinForGains Jul. 11 at 1:18 PM
$IRD sitting here with a 1.02 average. Trying to decide what a solid exit is without getting too greedy. I was thinking if it hits 1.50 ill definitely sell, but would probably sell at lower price points too. Just worried that theres not enough eyes/action for anything better.
0 · Reply
Maynard_Keysian
Maynard_Keysian Jul. 11 at 2:36 AM
$IRD After complaining, I will say presbyopia data is interesting. Take a drop at night and have full day effectiveness, plus for many get NVD benefits. LENZ data at a short number of hours after dosage, who cares, when you are sleeping with Ryzumvi (last 20 hours). With LENZ it will wear off at night when you are out to dinner, not good for business professionals. Plus, LENZ has far greater people reporting red eyes and other effects.
1 · Reply
Maynard_Keysian
Maynard_Keysian Jul. 11 at 2:29 AM
$IRD As has been pointed out, APX 3330 is not in the new Investor Presentation. Has the company given up? When George came aboard he praised APX, the company owes its shareholders clarity. I may start posting some of George's early interviews where he praises APX.
0 · Reply
signaljumper
signaljumper Jul. 10 at 5:16 PM
$IRD a close above 1.29$ and the paetty will start on this lowfloat gem
0 · Reply
DGains
DGains Jul. 10 at 4:48 PM
$NXTT Boom! 🎯 🚀 $BTCUSD.X Let’s FLY!! 🛫💹 $IRD Mentioned Start other day with $ECDA 😍💵
0 · Reply
DGains
DGains Jul. 10 at 12:53 PM
$NXTT Starting?! 😍🛫 $TSLA Too Easy 🏎️💵 $IRD Let’s RUN!! 💹😎 $ECDA Soon?! 🧐
0 · Reply
JussieLivermore
JussieLivermore Jul. 10 at 1:38 AM
$IRD not sure I believe APX deal rumors. We shall see, surprise me.
1 · Reply
jeremy50641
jeremy50641 Jul. 9 at 7:55 PM
$IRD more news should be coming
0 · Reply
signaljumper
signaljumper Jul. 9 at 7:32 PM
$IRD looking for 1.20 in the next days
0 · Reply
signaljumper
signaljumper Jul. 9 at 11:59 AM
$PROK at the Moment we are at 6$ so above 4.33$ next target are 8.87, 9.86, 12.13 and 13.08 Looking very strong Double Digits ? Follow me for more chart Setup and hot picks Loading $IRD
0 · Reply
signaljumper
signaljumper Jul. 9 at 7:59 AM
$PROK lowfloat biotech stocks running in the last 3 days here it is a bottomed biotech gem With a float of only 42M half of PROK they also have a great pipline Name is $IRD Buying at the bottom Loading since days
0 · Reply